News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cardiome Pharma Corp. Says Heart Drug Program Delayed, Shares Fall
August 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aug 11 (Reuters) - Canada's Cardiome Pharma Corp (COM.TO) said the development of its key drug to treat irregular heart beats will be delayed, sending its shares down as much as 18 percent on Wednesday morning.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
FDA
Approvals
MORE ON THIS TOPIC
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
October 8, 2025
·
2 min read
·
Annalee Armstrong
Approvals
Boehringer Ingelheim Breaks Decade-Long Approval Drought in Idiopathic Pulmonary Fibrosis
October 8, 2025
·
2 min read
·
Tristan Manalac
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
October 8, 2025
·
1 min read
·
Heather McKenzie
Regulatory
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator
October 7, 2025
·
1 min read
·
Heather McKenzie
